To purchase hard copies of this book, please email:
orders@intechopen.com
By only printing on demand InTech ensures our carbon footprint is kept to a minimum.
The data below shows the environmental impact of printing one single book:
83.98 kg wood
4.52 g CO2
76.25 ml Water
Share this page
Mechanisms in Parkinson's Disease - Models and Treatments
Edited by Juliana Dushanova, ISBN 978-953-307-876-2, Hard cover, 582 pages, Publisher: InTech, Published: February 08, 2012 under CC BY 3.0 license, in subject Mental and Behavioural Disorders and Diseases of the Nervous System
DOI: 10.5772/1826
Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.
This book is indexed in:
Book contents
- Chapter 1Update in Parkinson’s Disease
- Chapter 2Timing Control in Parkinson’s Disease
- Chapter 3Free Radicals, Oxidative Stress and Oxidative Damage in Parkinson's Disease
- Chapter 4The Execution Step in Parkinson’s Disease – On the Vicious Cycle of Mitochondrial Complex I Inhibition, Iron Dishomeostasis and Oxidative Stress
- Chapter 5Filterable Forms of Nocardia: An Infectious Focus in the Parkinsonian Midbrains
- Chapter 6Parkinson’s Disease and the Immune System
- Chapter 7Cyclin-Dependent Kinase 5 – An Emerging Player in Parkinson’s Disease Pathophysiology
- Chapter 8Regulation of a-Synuclein Membrane Binding and Its Implications
- Chapter 9Role of FKBPs in Parkinson’s Disease
- Chapter 10Targeting Tyrosine Hydroxylase to Improve Bradykinesia
- Chapter 11Wading into a Theoretical Model for Parkinson's Disease
- Chapter 12Successes of Modelling Parkinson Disease in Drosophila
- Chapter 13Parkinson’s Disease and Parkin: Insights from Park2 Knockout Mice
- Chapter 14Bilateral Distribution of Oxytocinase Activity in the Medial Prefrontal Cortex of Spontaneously Hypertensive Rats with Experimental Hemiparkinsonism
- Chapter 15Dictyostelium discoideum: A Model System to Study LRRK2-Mediated Parkinson Disease
- Chapter 16Comparison of Normal and Parkinsonian Microcircuit Dynamics in the Rodent Striatum
- Chapter 17Animal Models of Parkinson’s Disease Induced by Toxins and Genetic Manipulation
- Chapter 18Neuroprotective Effects of Herbal Butanol Extracts from Gynostemma pentaphyllum on the Exposure to Chronic Stress in a 6-Hydroxydopamine- Lesioned Rat Model of Parkinson's Disease Treated with or Without L-DOPA
- Chapter 19Acetyl-L-Carnitine in Parkinson’s Disease
- Chapter 20Distribution and Regulation of the G Protein- Coupled Receptor Gpr88 in the Striatum: Relevance to Parkinson’s Disease
- Chapter 21Human Lymphocytes and Drosophila melanogaster as Model System to Study Oxidative Stress in Parkinson's Disease
- Chapter 22Inflammation in Parkinson’s Disease: Causes and Consequences
- Chapter 23Neurotensin as Modulator of Basal Ganglia- Thalamocortical Motor Circuit – Emerging Evidence for Neurotensin NTS1 Receptor as a Potential Target in Parkinson's Disease
- Chapter 24Application of Embryonic Stem Cells in Parkinson’s Disease
- Chapter 25The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson’s Disease
- Chapter 26Noradrenergic Mechanisms in Parkinson’s Disease and L-DOPA-Induced Dyskinesia: Hypothesis and Evidences from Behavioural and Biochemical Studies
- Chapter 27Mitochondrial Haplogroups Associated with Japanese Parkinson’s Patients
- Chapter 28Role of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Parkinsonian Disorders
